CD19 and acute lymphoblastic leukemia: Lineage switch, a conversion between lymphoid and myeloid cell lineages during therapy resulting in the loss of CD19 expression, has been observed following CD19-directed CAR T cell therapy of ALL and blinatumomab treatment [81–83].